Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NHS-IL12 |
Synonyms | |
Therapy Description |
NHS-IL12 (M9241) is an immunocytokine composed of IL-12 linked to human tumor necrosis factor targeted IgG1, which may result in enhanced anti-tumor immune response (PMID: 24681847). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NHS-IL12 | M9241|M-9241 | NHS-IL12 (M9241) is an immunocytokine composed of IL-12 linked to human tumor necrosis factor targeted IgG1, which may result in enhanced anti-tumor immune response (PMID: 24681847). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05361798 | Phase II | NHS-IL12 | T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy | Recruiting | USA | 0 |
NCT01417546 | Phase I | NHS-IL12 | NHS-IL12 for Solid Tumors | Completed | USA | 0 |
NCT04303117 | Phase Ib/II | NHS-IL12 Bintrafusp alfa + NHS-IL12 | NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | Recruiting | USA | 0 |